Progress in blood cancers keeps ASH firmly in the spotlight

30 November 2018

The last couple of decades have seen huge breakthrough in HIV and hepatitis, but if a pharma advocate wanted to show someone from government what the industry is achieving right now with commitment to innovation, they would most likely point to immuno-oncology, and specifically what immunotherapies can achieve in blood cancers.

Novartis (NOVN: VX) and Gilead Sciences (Nasdaq: GILD) have both had groundbreaking CAR-T therapies approved in the USA and beyond for blood cancers in the last 18 months, hailed as a major moment in science and medicine.

This means that in recent years, the meeting of the American Society of Hematology (ASH) has arguably been just as eagerly awaited as the oncology-focused ASCO and ESMO conferences, and this year is no different.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK